Genovis AB (FRA:5GV) Debt-to-Asset : 0.00 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Genovis AB Debt-to-Asset?

Genovis AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Genovis AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Genovis AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was €28.13 Mil. Genovis AB's debt to asset for the quarter that ended in Sep. 2024 was 0.00.

Genovis AB Debt-to-Asset Historical Data

The historical data trend for Genovis AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB Debt-to-Asset Chart

Genovis AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.10

0.06

0.02

0.05

0.28

Genovis AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	0.28	-	-	-

Competitive Comparison of Genovis AB's Debt-to-Asset

For the Biotechnology subindustry, Genovis AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genovis AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovis AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genovis AB's Debt-to-Asset falls into.

Genovis AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genovis AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.403	+	6.688)	/	25.823
	=	0.27

Genovis AB's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	28.129
	=	0.00

Genovis AB (FRA:5GV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Genovis AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Genovis AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovis AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (FRA:5GV) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

GENO:Sweden

Address

Scheelevagen 2, Box 790, Lund, SWE, SE-220 07

Website

https://www.genovis.com

Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines